WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
Informaticians from Georgetown and other major cancer centers expect their technology to bring precision oncology services to community hospitals and clinics.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
With its technology, the company hopes to connect more cancer patients being treated in community-based practices to beneficial clinical trials based on genomic biomarkers.
